

CURRICULUM VITAE

RAVI R. IYER, MD

FOUNDING PHYSICIAN & PRINCIPAL INVESTIGATOR

THE IYER CLINIC – LMG (Adult & Geriatric Internal Medicine Clinic)

CLINICS & RESEARCH SITES:

1) The Iyer Clinic – HERNDON

13505 Dulles Technology Drive, Suite 1A
HERNDON, VA 20171

2) The Iyer Clinic – STERLING

21495 Ridgetop Circle, Suite 102
Sterling, VA 20166

3) The Iyer Clinic – Stone Springs

Stone Springs Blvd., Suite 100
Dulles, VA 20166

Clinic Phone:	(703) 404-5900
Research Phone (Common for all sites)	(571) 407-3285;
After Hours Research OnCall Line:	(571) 407-3285
Fax:	(703) 421-1099
E-mail-1:	river@imgdoctors.com
E-mail-2:	driyer@iyerclinic.com
Research Website:	
Clinic Website:	www.iyerclinic.com

POSITIONS / APPOINTMENTS:

Current Positions:

Director of Clinical Research,, Loudoun Medical Group, Leesburg, VA: June 2022 to present date – Consultant Research & Sites Director for the Clinical Research Division of Loudoun Medical Group

Chairman & CEO of ActivPower Inc. May 2016 to present date – ActivPower Inc. is a Delaware Company creating innovative herbal supplement & wellness products for Human & Animal Markets.

Founding Physician of The Iyer Clinic : 11/1/1997 to present date – An Adult Medicine and Geriatric clinical practice operating out of two offices located in Herndon, Aldie/South Riding and Sterling, VA.

President, Nova Health Mgmt & Research Group, PC : 11/1/1997 to present date --- Health Mgmt & Research Consulting Company engaged in helping client organizations in business development and research competency acquisition

Past Positions:

Medical Advisor, The Medical Team: Nov. 15th, 2013 to June 30, 2016

Advisory Board Member of a National Home Health Agency.

Chairman, Dept. of Medicine, Reston Hospital Ctr., Reston, VA--- 1/1/2012 to 12/31/2015

Vice-Chairman, Dept. of Medicine, Reston Hospital Ctr., Reston, VA --- 1/1/2008 to 12/31/2011

**Facility Physician Leader & Chair, Physician Advisory Group, Reston Hospital Ctr., Reston, VA
---- 10/1/2013 to April 30th 2014**

Wave 4 Advanced Clinical Implementation Leader & Transformation Management Agent for Hospital wide Implementation of Health Informatics system and Physician adoption

Medical Director, Heartland Hospice, Fairfax, VA ---- 10/1/2004 to 12/31/2013 – Hospice organization providing Community service and serving the terminally ill in Northern Virginia

Chairman and Director, Research & Development, Predictive Health Care Systems, Inc ---- 1997-2000

Chairman & Director of Disease Management R&D, Predictive Health Care Systems Inc., a Healthcare Information systems and Disease Management company involved with development and implementation of innovative approaches to chronic disease management programs.

EDUCATION & TRAINING

1] Internal Medicine Residency:

(Oct.1993 -to- Sept.1996)

Program Director :

**George Washington University Medical Center,
Washington, DC**

**Dr. Beth Horowitz, MD, Assoc. Professor of Medicine,
GWUMC Washington, DC.**

2] Fellowship:

(July 1991 -to- Sept.1993)

Supervisor :

Research Fellow in Medicine, Children's Hospital, Boston

- with dual appointment as - Research Fellow in Pediatrics,

Harvard Medical School, Boston

Dr. R. Alan B. Ezekowitz, MB.ChB., D.Phil (Former Assoc. Professor of Pediatrics, Children's Hospital, Boston) and currently ---
Professor & Chairman, Dept. of Pediatrics,
Massachusetts General Hospital, Boston.

3] Fellowship:

(July 1988 -to- June 1991)

Supervisor :

Research Fellow in Medicine, Massachusetts General Hospt.

Cancer Center, Boston - with dual appointment as - Research Fellow in Medicine, **Harvard Medical School, Boston.**

Dr. Kurt J. Isselbacher, MD, Mallinckrodt Professor of Medicine & Director, MGH Cancer Ctr. & Harvard Medical School, Boston.

4] Doctoral Degree[§](MD) :

(July 1985 -to- June 1988)

Doctor of Medicine in Biochemistry (MD-Biochem)

from Dept. of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.

5] Surgical Residency (6 mos):

(Feb.1985 -to- June 1985)

Jr. Resident Surgical House-Officer, Dept. of Surgery,

Nalanda Medical College, Patna, India.

6] Internship* (Family Practise):

(Feb.1984 -to- Jan.1985)

Nalanda Medical College, Patna, India.

7] Medical Education **: Nalanda Medical College, Patna, India.
(MB.BS. degree awarded in Jan.1984)

§ The M.D. (Biochem.) Doctor of Medicine degree in Biochemistry is a 3 yr. graduate program (equivalent to the Ph.D. component of the US. MD-Ph.D. joint program)
* Internship included Medicine, Surgery, Ob/Gyn and Pediatric rotations similar to a Family Practise Internship in the U.S.
** MB.BS. (Bachelor of Medicine & Bachelor of Surgery) equivalent to the MD degree in the U.S.

CLINICAL INTERESTS

Special interests include Long-COVID, Gastroenterology, Diabetes, Cardiology and Pulmonary/Reactive airways disease, Arthritis, Rheumatologic and Neuropathic diseases

RESEARCH EXPERIENCE

CLINICAL RESEARCH ACTIVITY:

- 1. DIABETES & CARDIOVASCULAR OUTCOME --- ClinicalTrials.gov Identifier: NCT01897532**
PRINCIPAL INVESTIGATOR in CARMELINA: Protocol No. BI 1218.22 A PHASE IV MULTICOUNTRY, MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY ON LONGTERM CARDIOVASCULAR OUTCOMES IN DIABETICS WITH RENAL INSUFFICIENCY.
- 2. DYSLIPIDEMIA & CARDIOVASCULAR OUTCOME --- ClinicalTrials.gov Identifier: NCT01408303**
PRINCIPAL INVESTIGATOR in STRENGTH: Protocol No. OM-EPA-005 A LONG-TERM OUTCOMES STUDY TO ASSESS STATIN RESIDUAL RISK REDUCTION WITH EPANOVA IN HIGH CARDIOVASCULAR RISK PATIENTS WITH HYPERTRIGLYCERIDEMIA
- 3. DIABETES --- ClinicalTrials.gov Identifier: NCT03136484**
PRINCIPAL INVESTIGATOR in SUSTAIN-8: Protocol No. NN9535-4270 EFFICACY AND SAFETY OF SEMAGLUTIDE VERSUS CANGLIFLOZINAS ADD-ON TO METFORMIN IN PATIENTS WITH TYPE-2 DIABETES
- 4. DYSLIPIDEMIA & CARDIOVASCULAR OUTCOME --- ClinicalTrials.gov Identifier: NCT03071692**
PRINCIPAL INVESTIGATOR in PROMINENT Protocol No. K-877-302 PROMINENT: PERMAFIBRATE TO REDUCE CARDIOVASCULAR OUTCOMES BY REDUCING TRIGLYCERIDES IN PATIENTS WITH DIABETES
- 5. POST-HERPETIC NEURALGIA— ClinicalTrials.gov Identifier: NCT01757873**
PRINCIPAL INVESTIGATOR Z160-PHN-202: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF Z160 IN SUBJECTS WITH POSTHERPETIC NEURALGIA
- 6. DIABETES & CARDIOVASCULAR OUTCOME --- ClinicalTrials.gov Identifier: NCT01703208**
PRINCIPAL INVESTIGATOR PROTOCOL NO. MK-3102-018: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH MK-3102 IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
- 7. CHRONIC CONSTIPATION --- ClinicalTrials.gov Identifier: NCT01982240**
PRINCIPAL INVESTIGATOR SP304203-03: A NATIONAL, RANDOMIZED, 12-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF PLECANATIDE (3.0 AND 6.0 MG) IN PATIENTS WITH CHRONIC IDIOPATHIC CONSTIPATION
- 8. GOUT --- ClinicalTrials.gov Identifier: NCT02128490**

PRINCIPAL INVESTIGATOR PROTOCOL NO. FEB-XR_301: A PHASE 2, RANDOMIZED, DOUBLE BLIND, MULTICENTER, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FEBUXOSTAT 40 MG XR, 80 MG XR, 40 MG IR AND 80 MG IR IN SUBJECTS WITH GOUT AND MODERATE RENAL IMPAIRMENT

9. COPD --- ClinicalTrials.gov Identifier: NCT02157935

PRINCIPAL INVESTIGATOR PROTOCOL NO. D589UC00001: A PHASE IIIB, 6-MONTH, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PARALLEL-GROUP, MULTICENTER EXACERBATION STUDY OF SYMBICORT® PMDI 160/4.5 MG X 2 ACTUATIONS TWICE-DAILY COMPARED TO FORMOTEROL TURBUHALER 4.5 MG X 2 INHALATIONS TWICE-DAILY IN COPD PATIENTS

10. PULMONARY HYPERTENSION AND INTERSTITIAL LUNG DISEASE --- ClinicalTrials.gov Identifier: NCT02036970

PRINCIPAL INVESTIGATOR in LARIAT: Protocol No. RTA 402-C-1302 A DOSE RANGING STUDY OF THE EFFICACY AND SAFETY OF BARDOXALONE METHYL IN PATIENTS WITH PULMONARY HYPERTENSION

BASIC RESEARCH EXPERIENCE:

Research experience spanning 8 years (1985-1993) has been in the fields of Biochemistry, Molecular Biology, Cell Biology, Immunology and Microbiology. The above training was obtained after the basic physicians training (MB.BS.) in India and after completion of a Family Practise Internship and a 6 month Surgical residency training in India. My doctoral training (1985-1988) culminating with the award of the Doctor of Medicine (M.D.) degree in Biochemistry was followed by a 5 year postdoctoral training at Harvard Medical School focussed on the molecular aspects of inflammation, sepsis and cytokine function.

PATENTS

- **Patent application on the recombinant DNA cat vectors pBRAMS cat1 and pBRAMS cat2** was filed by the Office of Technology Affairs, MGH, Boston. Ravi R. Iyer as the **sole inventor** on the application.
- **Patent No. 62/341,495 granted by USPTO on May 25, 2016 for Animal Resistance Training System** to Ravi R. Iyer
- **Patent No. 62/442,609 granted by USPTO on Jan 5, 2017 for Novel Herbal Liniment for Muscle and Jpoint Health, Recovery from Exertion and for Pain Management** to Ravi R. Iyer

AWARDS / HONORS

- TOP DOCTOR AWARD BY Northern Virginia Magazine for the years 2022, 2021, 2020, 2019, 2018, 2017, 2016, 2015, 2014**
- TOP DOCTOR AWARD (NATIONWIDE) BY Patient Fusion 2013**

AWARD PRESENTATIONS

- George Washington Univ. American College of Physicians Representative (1996) :- Podium presentation of "Silent Myocardial Infarction presenting as Embolic Visceral Infarcts" at the 1996 Regional (Washington, DC Area) Meeting of the American College of Physicians.**
- George Washington Univ. American College of Physicians Representative (1995) :- Selected as the Resident Representative from George Washington University Medical Center to give an Oral Presentation of "A Case Of Mesenteric Ischemia Precipitated By An Iliac Steal Syndrome" at the 1995 Regional (Washington, DC Area) Meeting of the American College of Physicians.**
- American Federation for Clinical Research Trainee Investigator Award (1992) :- Awarded the 1992 Trainee Investigator Award from the American Federation for Clinical Research, for oral presentation of a paper "Gamma**

interferon specific induction of the human FcγRI (CD64) gene is regulated by a novel response element”, at the Annual Scientific meeting of the AAP, AFRC & ASCI, May1-4, 1992, Baltimore, MD.

- D. CSIR (India) Young Scientist Travel Award (1987) :-** Awarded the **1987 Young Scientist Travel award** from the **Council for Scientific & Industrial Research (CSIR), Govt. of India** to attend and present a poster on research in leprosy at **The NATO Advanced Research Workshop on Bacteria, Complement and the Phagocytic Cell**, April 6-10, 1987, Villa Del Mare, Maratea, Italy.

PUBLICATIONS

- 1) **R.R. Iyer**, Molecular Biology for the Cardiologist. **Manuscript in press Journal of Nuclear Cardiology, 1998.**
- 2) G. Krishna and **R.R. Iyer**. "Animal models of Rheumatic Fever and Rheumatic Carditis" in *Rheumatic Fever* [J. Narula, K. S. Reddy, R. Tandon and R. Virmani eds.]. Oxford University Press. 1999. **Manuscript in press.**
- 3) **R.R. Iyer**, G. Krishna, M. Cunningham, M. Kotb and J. Narula. The Immunological basis of Rheumatic Carditis: Fresh insights into an old disease. **Manuscript under peer review for publication as Review Article in Circulation, 1999.**
- 4) †*Q.G. Eichbaum, **R.R. Iyer**, D.P. Raveh, C. Matheiu and R.A.B. Ezekowitz. Restriction of Interferon γ responsiveness and basal expression of the myeloid human FcγR1b gene is mediated by a functional Pu.1 box and a transcription initiator consensus. **J. Exp. Med. (1994) Vol.179 : 1985 - 1996.**
- 5) I. Rosenberg, **R.R. Iyer**, B. Cherayil and S. Pillai. Structure of the murine Mac-2 gene: Splice variants encode proteins lacking functional signal peptides. **J. Biol. Chem. (1993) Vol.268 (17) : 12393 - 12400.**
- 6) P.D. Benech, K.N. Sastry, **R.R. Iyer**, and R.A.B. Ezekowitz. Definition of interferon γ - response elements in a novel Human Fcγ receptor gene (FcγRIb) and characterization of the gene structure. **J. Exp. Med. 1992. 176: 1115 - 1123.**
- 7) **R.R. Iyer**. A matched set of CAT vectors for rapid mutational analysis of eukaryotic promoters and enhancers. **Gene. 1991; 105: 97-100.**
- 8) **R.R. Iyer**, H.K. Prasad, L.K. Bhutani, and D.N. Rao. Effect of tuftsin stimulation on the microbicidal activity exerted by blood monocyte-macrophages of leprosy patients. **Int. J.Immunopharmacol. 1990; 12(8): 859-869.**
- 9) **R.R. Iyer**, H.K. Prasad, L.K. Bhutani, and D.N. Rao. Modulation of human lepromatous monocyte-macrophage functions in vitro by tuftsin. **Int. J. Immunopharmacol. 1990;12(8): 847-858.**
- 10) D.N. Rao, **R.R.Iyer**, H.K. Prasad, and I. Nath. A novel synthetic route to a phagocytosis stimulating tetrapeptide "tuftsin". **Med. Sci. Res. 1987; 15: 1199-1201.**

†* *Joint first authorship with Q.G.E.*

CLINICAL GRAND GROUNDS & TALKS:

1. **Molecular Biology for the Cardiologist: Part 1. Oct. 15th, 1997.** Grand Round Lecture Series in Molecular Cardiology. Dept of Cardiology, Medical College of Pennsylvania-Hahnemann, Allegheny University, Philadelphia, PA.
2. **Caring for the Alzheimer's Patient. Oct. 16th, 1997.** Graceful Care, Reston VA.
3. **Chronic Health Management: Problems & Opportunities for a Quality Life. Nov. 4th, 1997.** Sunrise Assisted Living, Hunter Mill Road, Vienna, VA.
4. **Molecular Biology for the Cardiologist: Part 2. Nov. 19th, 1997.** Grand Round Lecture Series in Molecular Cardiology. Dept of Cardiology, Medical College of Pennsylvania-Hahnemann, Allegheny University, Philadelphia, PA.

PODIUM PRESENTATIONS & POSTER ABSTRACTS

1. †/J. Sunew, G. Krishna, and **R.R. Iyer**. Silent Myocardial Infarction presenting as Embolic Visceral Infarcts. Regional ACP **Podium Presentation** (Jan.1996)
2. †/ **R.R. Iyer**, M. Baig, Y.Y. Zhu and G. Krishna. A Case Of Mesenteric Ischemia Precipitated By An Iliac Steal Syndrome. Regional ACP **Podium Presentation** (Jan.1995)
3. §§ Ganesh, K., W. Eves, **R.R. Iyer** and R.P. Wagner. A Case Of Diffuse Infiltrative Lymphocytosis As An Immunogenetic Host Response To HIV Antigen. Regional ACP Abstract (Jan.1995)
4. §§ Allende, M., and **R.R. Iyer**. A Case Of Massive Pleural Effusion Due To PatPancreatico-Pleural Fistula. Regional ACP Abstract (Jan.1995)
5. * **R.R. Iyer**, D. Raveh, P.D. Benech and R.A.B. Ezekowitz. Gamma interferon specific induction of the human FcγRI (CD64) gene is regulated by a novel response element. Clin.Res. 1992. 40(2): 212A.
6. * **R.R. Iyer**, Q.G. Eichbaum, D.P. Raveh and R.A.B. Ezekowitz. Definition of the IFN- γ response element of the FcγRI (CD64) gene promoter: Evidence for a novel IFN- γ induced DNA binding protein. Clin. Res. 1993. 41(2): 184A.
7. § **R.R. Iyer**, P.D. Benech, K.N. Sastry, and R.A.B. Ezekowitz. A novel gamma interferon response element regulates induction of the human CD64 gene. J. Cell. Biochem. 1992Suppl. 16A: 103.

8.**Eichbaum Q.G., **R.R. Iyer**, D.P. Raveh, and R.A.B. Ezekowitz. A novel cis element appears to restrict myeloid expression of the CD64 (FcγRI) gene. Clin. Res. 1993. 41(2): 307A

* *Podium presentations at the 1992 and 1993 Annual Meeting of the Association of American Physicians (AAP), American Society for Clinical Investigation (ASCI) & American Federation for Clinical Research (AFCR).*

¶ *Podium Presentation at the Regional (Washington, DC Area) Meeting of the American College of Physicians, Jan. 1995.*

§ *Poster presentations at the 1991 Keystone Symposia (#3) and the **1993 Annual Meeting of the AAP, ASCI & AFCR (#4).*

§§ *Poster Presentation at the Regional (Washington, DC Area) Meeting of the American College of Physicians, Jan. 1995.*

OTHER SKILLS / INTERESTS / AFFILIATIONS

- Active Full Member:
 - United Schutzhund Clubs of America
 - German Shepherd Dog Club of America
 - DVG America
 - Blitzburg Hundesport Club
 - South Metro Atlanta Schutzhund Club